Related Experiment Videos

A novel deletion in the RET proto-oncogene found in sporadic medullary thyroid carcinoma

M Alemi1, S D Lucas, J F Sällström

  • 1Department of Pathology, University of Uppsala, University Hospital, Sweden.

Anticancer Research
|September 1, 1996
PubMed

Insights

This study identified a novel RET proto-oncogene mutation in sporadic medullary thyroid carcinoma. This finding further implicates RET in the development of aggressive thyroid tumors.

Area of Science:

  • Oncology
  • Genetics
  • Endocrinology

Background:

  • Germ line mutations in the RET proto-oncogene are linked to inherited endocrine disorders like MEN 2A, MEN 2B, FMTC, and Hirschsprung's disease.
  • Somatic RET mutations are found in sporadic medullary thyroid tumors, often in regions associated with MEN 2B.

Purpose of the Study:

  • To investigate the role of the RET proto-oncogene in sporadic medullary thyroid carcinoma (MTC).
  • To identify novel mutations in sporadic MTC tumors.

Main Methods:

  • Screening of archival sporadic MTC tumor tissue using nonradioactive single-strand conformational polymorphism analysis (SSCP).
  • DNA sequencing of PCR amplified DNA from tumor and normal thyroid tissue.

Main Results:

  • A divergent exon 11 SSCP pattern was identified in an aggressive sporadic MTC neoplasm.
  • Sequencing revealed a novel nine-base deletion in exon 11 of the RET proto-oncogene, affecting a key cysteine codon.
  • The same patient's normal thyroid tissue showed a normal sequence for this exon.

Conclusions:

  • This novel somatic mutation in the RET proto-oncogene provides further evidence for its role in the pathogenesis of medullary thyroid carcinoma.
  • The findings highlight the importance of RET mutations in both inherited and sporadic forms of MTC.

Related Concept Videos